Reduced CD26bright expression of peripheral blood CD8+ T-cell subsets in psoriatic patients

Experimental Dermatology

Volumn 17, Issue 4, 2008, Pages 343-348

  van Lingen, Rosanne G ^a   van de Kerkhof, Peter C M ^a   de Jong, Elke M G J ^a   Seyger, Marieke M B ^a   Boezeman, Jan B M ^a   van Erp, Piet E J ^a  

^a RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

CD26; Peripheral blood; Psoriasis; T cells

Indexed keywords

BIOLOGICAL MARKER; CD45RO ANTIGEN; DIPEPTIDYL PEPTIDASE IV;

ADULT; ARTICLE; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CLINICAL ARTICLE; CONTROLLED STUDY; CORRELATION ANALYSIS; DISEASE SEVERITY; FEMALE; FLOW CYTOMETRY; HUMAN; HUMAN CELL; LYMPHOCYTE FUNCTION; MALE; PROTEIN EXPRESSION; PSORIASIS; T LYMPHOCYTE ACTIVATION; T LYMPHOCYTE SUBPOPULATION;

ADULT; ANTIBODIES, MONOCLONAL; ANTIGENS, CD26; ANTIGENS, CD45; CD4-POSITIVE T-LYMPHOCYTES; CD8-POSITIVE T-LYMPHOCYTES; FEMALE; FLOW CYTOMETRY; HUMANS; INTERLEUKIN-2 RECEPTOR ALPHA SUBUNIT; MALE; MIDDLE AGED; PSORIASIS;

EID: 40349098214     PISSN: 09066705     EISSN: 16000625     Source Type: Journal    
DOI: 10.1111/j.1600-0625.2007.00650.x     Document Type: Article

References (42)

1. Austin LM, Ozawa M, Kikuchi T, Walters IB, Krueger JG. The majority of epidermal T cells in Psoriasis vulgaris lesions can produce type 1 cytokines, interferon-gamma, interleukin-2, and tumor necrosis factor-alpha, defining TC1 (cytotoxic T lymphocyte) and TH1 effector populations: A type 1 differentiation bias is also measured in circulating blood T cells in psoriatic patients. J Invest Dermatol 1999: 113: 752-759.
2. Kormeili T, Lowe NJ, Yamauchi PS. Psoriasis: Immunopathogenesis and evolving immunomodulators and systemic therapies; U.S. experiences. Br J Dermatol 2004: 151: 3-15.
3. Lowes MA, Bowcock AM, Krueger JG. Pathogenesis and therapy of psoriasis. Nature 2007: 445: 866-873.
4. Schlaak JF, Buslau M, Jochum W et.al. T cells involved in psoriasis vulgaris belong to the Th1 subset. J Invest Dermatol 1994: 102: 145-149.
5. Nickoloff BJ. Cracking the cytokine code in psoriasis. Nat Med 2007: 13: 242-244.
6. Gordon KB, Vaishnaw AK, O'Gorman J, Haney J, Menter A. Treatment of psoriasis with alefacept: Correlation of clinical improvement with reductions of memory T-cell counts. Arch Dermatol 2003: 139: 1563-1570.
7. Jullien D, Prinz JC, Langley RG et.al. T-cell modulation for the treatment of chronic plaque psoriasis with efalizumab (Raptiva): mechanisms of action. Dermatology 2004: 208: 297-306.
8. Menter A, Gordon K, Carey W et.al. Efficacy and safety observed during 24weeks of efalizumab therapy in patients with moderate to severe plaque psoriasis. Arch Dermatol 2005: 141: 31-38.
9. Kauffman CL, Aria N, Toichi E et.al. A phase I study evaluating the safety, pharmacokinetics, and clinical response of a human IL-12 p40 antibody in subjects with plaque psoriasis. J Invest Dermatol 2004: 123: 1037-1044.
10. Boonacker E, Van Noorden CJ. The multifunctional or moonlighting protein CD26/DPPIV. Eur J Cell Biol 2003: 82: 53-73.
11. Brezinschek RI, Lipsky PE, Galea P, Vita R, Oppenheimer-Marks N. Phenotypic characterization of CD4+ T cells that exhibit a transendothelial migratory capacity. J Immunol 1995: 154: 3062-3077.
12. Hegen M, Kameoka J, Dong RP, Morimoto C, Schlossman SF. Structure of CD26 (dipeptidyl peptidase IV) and function in human T cell activation. Adv Exp Med Biol 1997: 421: 109-116.
13. Morimoto C, Kameoka J, Tanaka T, Schlossman SF. Overview of CD26. In: Schlossman SF, Boumsell L, Gilks W et.al., eds. Leucocyte Typing V: White Cell Differentiation Antigens. Madison Avenue, NY, USA, Oxford University Press, 1995: 1105-1114.
14. Torimoto Y, Dang NH, Vivier E, Tanaka T, Schlossman SF, Morimoto C. Coassociation of CD26 (dipeptidyl peptidase IV) with CD45 on the surface of human T lymphocytes. J Immunol 1991: 147: 2514-2517.
15. Ulmer AJ, Mattern T, Flad HD. Expression of CD26 (dipeptidyl peptidase IV) on memory and naive T lymphocytes. Scand J Immunol 1992: 35: 551-559.
16. Geppert TD, Davis LS, Gur H, Wacholtz MC, Lipsky PE. Accessory cell signals involved in T-cell activation. Immunol Rev 1990: 117: 5-66.
17. DeMeester I, Korom S, Van DJ, Scharpe S. CD26, let it cut or cut it down. Immunol Today 1999: 20: 367-375.
18. Boonacker EP, Wierenga EA, Smits HH, Van Noorden CJ. CD26/DPPIV signal transduction function, but not proteolytic activity, is directly related to its expression level on human Th1 and Th2 cell lines as detected with living cell cytochemistry. J Histochem Cytochem 2002: 50: 1169-1177.
19. Novelli M, Savoia P, Fierro MT, Verrone A, Quaglino P, Bernengo MG. Keratinocytes express dipeptidyl-peptidase IV (CD26) in benign and malignant skin diseases. Br J Dermatol 1996: 134: 1052-1056.
20. Munoz E, Blazquez MV, Madueno JA, Rubio G, Pena J. CD26 induces T-cell proliferation by tyrosine protein phosphorylation. Immunology 1992: 77: 43-50.
21. Hafler DA, Fox DA, Benjamin D, Weiner HL. Antigen reactive memory T cells are defined by Ta1. J Immunol 1986: 137: 414-418.
22. Morimoto C, Schlossman SF. The structure and function of CD26 in the T-cell immune response. Immunol Rev 1998: 161: 55-70.
23. Blazquez MV, Madueno JA, Gonzalez R et.al. Selective decrease of CD26 expression in T cells from HIV-1-infected individuals. J Immunol 1992: 149: 3073-3077.
24. Cordero OJ, Salgado FJ, Mera-Varela A, Nogueira M. Serum interleukin-12, interleukin-15, soluble CD26, and adenosine deaminase in patients with rheumatoid arthritis. Rheumatol Int 2001: 21: 69-74.
25. Eguchi K, Ueki Y, Shimomura C et.al. Increment in the Ta1+ cells in the peripheral blood and thyroid tissue of patients with Graves' disease. J Immunol 1989: 142: 4233-4240.
26. Gerli R, Muscat C, Bertotto A et.al. CD26 surface molecule involvement in T cell activation and lymphokine synthesis in rheumatoid and other inflammatory synovitis. Clin Immunol Immunopathol 1996: 80: 31-37.
27. Hafler DA, Fox DA, Manning ME, Schlossman SF, Reinherz EL, Weiner HL. In vivo activated T lymphocytes in the peripheral blood and cerebrospinal fluid of patients with multiple sclerosis. N Engl J Med 1985: 312: 1405-1411.
28. Vanham G, Kestens L, De M I et.al. Decreased expression of the memory marker CD26 on both CD4+ and CD8+ T lymphocytes of HIV-infected subjects. J Acquir Immune Defic Syndr 1993: 6: 749-757.
29. Bock O, Kreiselmeyer I, Mrowietz U. Expression of dipeptidyl-peptidase IV (CD26) on CD8+ T cells is significantly decreased in patients with psoriasis vulgaris and atopic dermatitis. Exp Dermatol 2001: 10: 414-419.
30. Masuyama J, Berman JS, Cruikshank WW, Morimoto C, Center DM. Evidence for recent as well as long term activation of T cells migrating through endothelial cell monolayers in vitro. J Immunol 1992: 148: 1367-1374.
31. Baker BS, Swain AF, Fry L, Valdimarsson H. Epidermal T lymphocytes and HLA-DR expression in psoriasis. Br J Dermatol 1984: 110: 555-564.
32. Bos JD, Hulsebosch HJ, Krieg SR, Bakker PM, Cormane RH. Immunocompetent cells in psoriasis. In situ immunophenotyping by monoclonal antibodies. Arch Dermatol Res 1983: 275: 181-189.
33. Bovenschen HJ, Seyger MM, Van de Kerkhof PC. Plaque psoriasis vs. atopic dermatitis and lichen planus: A comparison for lesional T-cell subsets, epidermal proliferation and differentiation. Br J Dermatol 2005: 153: 72-78.
34. Gaspari AA. Innate and adaptive immunity and the pathophysiology of psoriasis. J Am Acad Dermatol 2006: 54: S67-S80.
35. Van de Kerkhof PC. The evolution of the psoriatic lesion. Br J Dermatol 2007: 157: 4-15.
36. Vissers WH, Arndtz CH, Muys L, Van Erp PE, de Jong EM, Van de Kerkhof PC. Memory effector (CD45RO+) and cytotoxic (CD8+) T cells appear early in the margin zone of spreading psoriatic lesions in contrast to cells expressing natural killer receptors, which appear late. Br J Dermatol 2004: 150: 852-859.
37. Plant D, Young HS, Watson RE, Worthington J, Griffiths CE. The CX3CL1-CX3CR1 system and psoriasis. Exp Dermatol 2006: 15: 900-903.
38. Krakauer M, Sorensen PS, Sellebjerg F. CD4(+) memory T cells with high CD26 surface expression are enriched for Th1 markers and correlate with clinical severity of multiple sclerosis. J Neuroimmunol 2006: 181: 157-164.
39. Muscat C, Bertotto A, Agea E et.al. Expression and functional role of 1F7 (CD26) antigen on peripheral blood and synovial fluid T cells in rheumatoid arthritis patients. Clin Exp Immunol 1994: 98: 252-256.
40. Bachelez H. Immunopathogenesis of psoriasis: Recent insights on the role of adaptive and innate immunity. J Autoimmun 2005: 25 (Suppl): 69-73.
41. Bos JD, de Rie MA, Teunissen MB, Piskin G. Psoriasis: Dysregulation of innate immunity. Br J Dermatol 2005: 152: 1098-1107.
42. Nickoloff BJ. Skin innate immune system in psoriasis: Friend or foe? J Clin Invest 1999: 104: 1161-1164.